Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients (PRO-RED)
Longitudinal, App-based Assessment of Varying Red Blood Cell Transfusion Strategies and Their Association With Patient-Reported, Clinical and Economical Outcomes in Lower-risk Myelodysplastic Neoplasms (MDS) Patients
Sponsor: Deutsche Krebshilfe e.V., Bonn (Germany)
A observational or N/A phase clinical study on MDS and MDS/MPN, this trial is ongoing. The trial is conducted by Deutsche Krebshilfe e.V., Bonn (Germany) and has accumulated 12 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Apr 16, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Apr 2026 [monthly]
Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 7 earlier versions
-
Feb 2024 — May 2024 [monthly]
Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting
-
Aug 2023 — Jan 2024 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
-
May 2023 — Jul 2023 [monthly]
Recruiting
-
Mar 2023 — May 2023 [monthly]
Recruiting
-
Nov 2022 — Mar 2023 [monthly]
Recruiting
First recorded
Oct 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
PRO-RED is a prospective, longitudinal, and multicenter observational study. Enrolled patients will be followed for 6 months in at least monthly intervals in terms of their received red blood cell transfusions and routine myelodysplastic neoplasms (MDS)-associated clinical parameters. In addition, the participating subjects will be provided with a digital/mobile application covering a smartphone app or paper-based questionnaires to answer a set of quality of life (QoL) questions once a week. During routine visits in the clinical trials center performed by the treating physician (at least every month), patients will answer standardized questionnaires for the assessment of MDS-related QoL. Also, included patients will take a photo of fingernails/eyelids with their smartphone camera with the aim to further analyze these pictures in a way to potentially deduct correlated hemoglobin (Hb)-values. As a long term aim beyond the PRO-RED study, the data will serve as a training cohort for the development of an algorithm for image-based calculation of individual Hb levels.
Contact Information
- Deutsche Krebshilfe e.V., Bonn (Germany)
- University of Leipzig
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Chemnitz, Germany , Dresden, Germany , Dresden, Germany , Düsseldorf, Germany , Innsbruck, Austria , Jena, Germany , Leipzig, Germany , Mainz, Germany , Mannheim, Germany and 1 more location